uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Adzynma
Authorised
Human
Orphan medicine
Details
EMA number
EMEA/H/C/006198
ATC code
B01AD13
Authorisation
1 August 2024
Revision
1
EMA page
Therapeutic indication
Treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency
MeSH:
Purpura, Thrombotic Thrombocytopenic
Group:
Antithrombotic agents;Enzymes
Special characteristics
Additional monitoring
Active substances
rADAMTS13
Marketing Authorisation Holder
Takeda Manufacturing Austria AG
MAH
Timeline
Filter by authority:
EMA
Adzynma authorised
1 Aug 2024
authorised
regulatory
Adzynma | uMedical